| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 |
|--|
| or Section 30(h) of the Investment Company Act of 1940                 |

| 1. Name and Address of Reporting Person*  |               |               | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Kiniksa Pharmaceuticals, Ltd.</u> [KNSA ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)                              |  |  |  |  |
|---|---------------|---------------|--|---|--|--|--|--|
| (Last) (First) (Middle)<br>C/O KINIKSA PHARMACEUTICALS, LTD.<br>CLARENDON HOUSE 2 CHURCH STREET |               |               | 3. Date of Earliest Transaction (Month/Day/Year)<br>07/15/2021                                     | Director 10% Owner   X Officer (give title<br>below) Other (specify<br>below)   Chief Operating Officer |  |  |  |  |
|   |               |               | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person  |  |  |  |  |
| HAMILTON<br>(City)  | D0<br>(State) | HM11<br>(Zip) | _  | Form filed by More than One Reporting<br>Person   |  |  |  |  |
|   | . ,           |               | vative Securities Acquired, Disposed of, or Bene   | l<br>aficially Owned  |  |  |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |                  |   | 4. Securities<br>Disposed Of<br>5) |               |               | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |  |
|---------------------------------|--|---|------------------|---|------------------------------------|---------------|---------------|---|---|---|--|--|
|                                 |  |   | Code             | v | Amount                             | (A) or<br>(D) | Price         | Transaction(s)<br>(Instr. 3 and 4)  |   | (1130.4)  |  |  |
| Class A Common Share            | 07/15/2021                                 |   | A <sup>(1)</sup> |   | 868                                | A             | \$11.49       | 106,810   | D   |   |  |  |
| Class A Common Share            | 01/15/2022                                 |   | A <sup>(2)</sup> |   | 970                                | A             | <b>\$9.63</b> | 107,780   | D   |   |  |  |
| Class A Common Share            | 03/16/2022                                 |   | М                |   | 1,964                              | A             | (3)           | 109,744   | D   |   |  |  |
| Class A Common Share            | 03/16/2022                                 |   | F                |   | 681                                | D             | \$10.13       | 109,063   | D   |   |  |  |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of<br>Deri<br>Sec<br>Acq<br>(A) (<br>Disp<br>of (I<br>(Inst | erivative (Month/Day/Year)<br>ecurities<br>cquired<br>A) or<br>isposed |                     | and 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                            | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | derivative<br>Securities<br>Beneficially<br>Owned | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|---|---|--|---|------------------------------|---|---|--|---------------------|--|----------------------------|---|---|--|--|--|
|   |   |  |   | Code                         | v | (A)   | (D)  | Date<br>Exercisable | Expiration<br>Date   | Title                      | Amount<br>or<br>Number<br>of<br>Shares              |   |  |  |  |
| Restricted<br>Share Unit                            | (3)   | 03/16/2022                                 |   | М                            |   |   | 1,964  | (4)                 | (4)  | Class A<br>Common<br>Share | 1,964   | \$0   | 5,892  | D  |  |

### Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

2. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

3. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

Madelyn Zeylikman, Attorney-03/18/2022 in-Fact for Eben Tessari

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.